Professor Hugenholtz is a microbiologist who has made contributions in the field of culture-independent analysis of microorganisms. He discovered and characterised numerous previously unrecognised major bacterial and archaeal lineages each with greater evolutionary divergence than animals and plants combined. He has participated in the development and application of metagenomics, the genome-based characterisation of microbiomes, which has revolutionised our understanding of microbial ecology and evolution. He has made several discoveries in environmental and clinical microbiology sometimes overturning decades of misdirected culture-based studies.
Animals are reliant on their gut microbiota (collectively called the microbiome) for health and well-being.
Bacillus amyloliquefaciens strain H57 was initially isolated for its ability to inhibit the growth of fungi that causes livestock feed to spoil.
Understanding the role of microbes in koala digestion and their potential to buffer digestive efficiency against the impacts of climate change as well as from translocation to areas with different species eucalyptus trees.
An important aspect of our work with host-associated microbiomes involves investigating members of these communities that have yet to be cultured within the laboratory.
Bone marrow and stem cell transplants are important therapies for cancers such as leukemia, lymphoma and myeloma that develop in blood forming tissues.
Chronic obstructive pulmonary disease (COPD) is used to describe a number of lung diseases that prevent proper breathing.
Marine microbes are tiny, they span only about 1/100 the diameter of a human hair, but they are very abundant in our oceans, accounting for over 90% of the biomass.
Taxonomic classification of living organisms and understanding their ancestry is the basis of all biology.
Squamous cell carcinoma (SCC) is the second most common form of skin cancer globally.